lncRNA PITPNA-AS1 promotes cell proliferation and metastasis in hepatocellular carcinoma by upregulating PDGFD.


Journal

Aging
ISSN: 1945-4589
Titre abrégé: Aging (Albany NY)
Pays: United States
ID NLM: 101508617

Informations de publication

Date de publication:
02 03 2023
Historique:
received: 10 10 2021
accepted: 11 02 2023
medline: 7 6 2023
pubmed: 31 5 2023
entrez: 30 5 2023
Statut: ppublish

Résumé

Hepatocellular carcinoma (HCC) ranks high in morbidity and mortality among notorious malignancies because of the lack of effective biomarkers and treatments. LncRNA PITPNA antisense RNA 1 (PITPNA-AS1) plays an oncogenic role in HCC, yet the mechanistic basis remains unprobed. Here using Bioinformatics and PCR analyses, we validated that PITPNA-AS1 expression was significantly increased in HCC. The levels of PITPNA-AS1 in tumors were reversely correlated with the prognosis in HCC patients. Downregulation of PITPNA-AS1 inhibited malignant activities of HCC cells. Next, we elucidated that PITPNA-AS1 acts as a competing endogenous RNA (ceRNA) to sponge miR-363-5p, thereby regulating the expression of platelet-derived growth factor-D (PDGFD). Moreover, the suppression of HCC cell activities by PITPNA-AS1 downregulation can be removed by PDGFD overexpression or miR-363-5p inhibition. Collectively, our work reveals the involvement of the PITPNA-AS1/miR-363-5p/PDGFD regulatory axis in HCC progression.

Identifiants

pubmed: 37253627
pii: 204566
doi: 10.18632/aging.204566
pmc: PMC10258019
doi:

Substances chimiques

RNA, Long Noncoding 0
MicroRNAs 0
Platelet-Derived Growth Factor 0
PDGFD protein, human 0
Lymphokines 0
MIRN363 microRNA, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4071-4083

Références

Bioengineered. 2022 Feb;13(2):3666-3679
pubmed: 35081873
Exp Ther Med. 2020 Aug;20(2):978-984
pubmed: 32742341
Curr Biol. 2014 Aug 18;24(16):R762-76
pubmed: 25137592
Front Med (Lausanne). 2021 May 12;8:668787
pubmed: 34055841
Mol Med Rep. 2017 Aug;16(2):1603-1611
pubmed: 28627662
Dig Liver Dis. 2022 Jan;54(1):125-135
pubmed: 34053876
Mol Cell. 2011 Sep 16;43(6):904-14
pubmed: 21925379
Nat Rev Mol Cell Biol. 2013 Nov;14(11):699-712
pubmed: 24105322
Cell Death Dis. 2018 Mar 16;9(4):417
pubmed: 29549306
Cancer Treat Rev. 2013 Oct;39(6):640-6
pubmed: 23261166
Cancer Lett. 2022 Mar 1;528:16-30
pubmed: 34958891
Oncotarget. 2013 Nov;4(11):1999-2009
pubmed: 24158561
Cell Death Dis. 2019 Nov 7;10(11):844
pubmed: 31700026
Biochim Biophys Acta. 2010 Aug;1806(1):122-30
pubmed: 20434526
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Genome Res. 2012 Sep;22(9):1775-89
pubmed: 22955988
Mol Med. 2018 Jul 31;24(1):40
pubmed: 30134837
Cell Death Dis. 2022 Jan 10;13(1):35
pubmed: 35013144
Cancer Genet. 2017 Oct;216-217:105-110
pubmed: 29025584
Ann Hepatol. 2022 Jan;27 Suppl 1:100567
pubmed: 34699986
Ann Surg Oncol. 2009 May;16(5):1254
pubmed: 19277788
J Cancer. 2022 Jan 4;13(3):1048-1060
pubmed: 35154469
Mol Oncol. 2021 Sep;15(9):2466-2479
pubmed: 34058065
Biomed Pharmacother. 2020 Aug;128:110072
pubmed: 32460193
Anticancer Res. 2013 Nov;33(11):4811-9
pubmed: 24222117
Adv Exp Med Biol. 2016;937:3-17
pubmed: 27573892
Stem Cells. 2009 Aug;27(8):1712-21
pubmed: 19544444
Lancet Oncol. 2012 Aug;13(8):750-1
pubmed: 22738800
Nature. 2013 Mar 21;495(7441):384-8
pubmed: 23446346
Gene. 2018 Mar 1;645:76-84
pubmed: 29248577
BMC Gastroenterol. 2017 Jun 20;17(1):81
pubmed: 28637446
Oxid Med Cell Longev. 2022 Jan 7;2022:1125932
pubmed: 35035655
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
World J Hepatol. 2016 Nov 8;8(31):1309-1317
pubmed: 27872682
Genes Chromosomes Cancer. 2019 Apr;58(4):191-199
pubmed: 30461116
Int J Mol Sci. 2015 Jan 08;16(1):1395-405
pubmed: 25580533

Auteurs

Jianguo Yao (J)

Department of Surgery, Tongxiang First People’s Hospital, Tongxiang 314500, Zhejiang, P.R. China.

Xiaojian Liu (X)

Department of Surgery, Tongxiang First People’s Hospital, Tongxiang 314500, Zhejiang, P.R. China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH